TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06566170: A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 6250 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT06566170 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06566170 Rescue Dossier →